Evidence map›Paper›PMID 41746580›Full record

ReviewMolecular biomedicine2026

Lactate metabolism and protein lactylation in cancer.

Zhaoyun Liu, Aili Li, Ziyu Ma, Junzhu Wang, Xinyu Chen, Zhiwei Wang, Rong Fu

Abstract readReview
In one paragraph

Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhaoyun Liu *Department of Hematology, Tianjin Medical University General Hospital, Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin Institute of Hematology, State Key Laboratory of Experimental Hematology, 154 Anshan Street, Heping District, Tianjin, 300052, China. liuzhaoyun114@163.com.
Aili Li *Department of Hematology, Tianjin Medical University General Hospital, Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin Institute of Hematology, State Key Laboratory of Experimental Hematology, 154 Anshan Street, Heping District, Tianjin, 300052, China.
Ziyu MaDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin Institute of Hematology, State Key Laboratory of Experimental Hematology, 154 Anshan Street, Heping District, Tianjin, 300052, China.
Junzhu WangDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin Institute of Hematology, State Key Laboratory of Experimental Hematology, 154 Anshan Street, Heping District, Tianjin, 300052, China.
Xinyu ChenDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin Institute of Hematology, State Key Laboratory of Experimental Hematology, 154 Anshan Street, Heping District, Tianjin, 300052, China.
Zhiwei WangDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin Institute of Hematology, State Key Laboratory of Experimental Hematology, 154 Anshan Street, Heping District, Tianjin, 300052, China.
Rong FuDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, Tianjin Institute of Hematology, State Key Laboratory of Experimental Hematology, 154 Anshan Street, Heping District, Tianjin, 300052, China. furong8369@tmu.edu.cn.ORCID http://orcid.org/0000-0002-9928-9224

Funding

Tianjin Health Research Project TJWJ2023XK003Tianjin Key Medical Discipline Construction Project TJYXZDXK-3-001A
6 · The paper itself

Abstract

Lactylation is a recently identified post-translational modification that links cellular metabolism to gene regulation, playing pivotal roles in cancer development and the tumor microenvironment (TME). Derived from lactate produced by glycolysis and glutamine metabolism, lactylation occurs on both histone and non-histone proteins, modulating transcription, protein function, and cellular signaling. In tumors, lactylation contributes to proliferation, metastasis, therapy resistance, and immune evasion by influencing the function of Treg cells, macrophages, dendritic cells, and NK cells. Its dynamic regulation by "writers" (e.g., p300), "erasers" (e.g., Histone deacetylases (HDACs), Sirtuins3 (SIRT3)), and transporters (e.g., monocarboxylate transporters (MCT) 1/4) provides multiple intervention points for therapy. Preclinical studies demonstrate that targeting lactylation directly or indirectly-through LDH (lactate dehydrogenase) inhibition, MCT blockade, or modulation of lactyltransferases-enhances the efficacy of immune checkpoint inhibitors, Chimeric Antigen Receptor T (CAR-T) therapy, and chemotherapeutic agents.Despite these advances, critical questions remain regarding the specificity of lactylation compared with other post-translational modifications, the tumor types most dependent on lactylation, and reliable biomarkers to guide treatment. Additionally, clinical validation of lactylation-targeting strategies is limited. Future research integrating mechanistic studies, patient-derived samples, and multi-omics approaches is essential to elucidate context-dependent functions, refine therapeutic targets, and develop precision interventions.This review provides a comprehensive summary of lactylation biology in cancer, highlighting its metabolic-epigenetic interplay, immunomodulatory roles, and therapeutic potential. By synthesizing current evidence, we aim to guide future studies and clinical strategies targeting lactylation to improve cancer treatment outcomes.

Indexed as

Lactic AcidNeoplasmsProtein Processing, Post-TranslationalAnimalsHumansMetabolic ReprogrammingMonocarboxylic Acid TransportersTumor MicroenvironmentLactic AcidMonocarboxylic Acid TransportersCancer therapyHistone modificationImmune evasionLactylationLDHTumor microenvironment

Identifiers

PMID41746580
PMCPMC12946641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.